Significant Agreements - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended
	Dec. 16, 2019	Feb. 28, 2021	Jun. 30, 2021	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Value, New Issues			$ 167,045
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues			11,500,000
Stock Issued During Period, Value, New Issues			$ 1
Takeda Asset Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront of cash payment	$ 1,000
Takeda Asset Agreement [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares	6,470,382
Takeda Asset Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues				9,857,143
Stock Issued During Period, Value, New Issues	$ 9,900
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares	9,857,143
Takeda Asset Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment				$ 8,000
Merck License Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones				2,500
Merck License Agreement [Member] | Research and Development Expense [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones				$ 364,500
Viracta License Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones		$ 54,000
Viracta License Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones		$ 3,000
Upfront of cash payment	$ 2,000